Diagnostic and prognostic potential of modern biomarkers in community-acquired pneumonia in children

Belykh N.A.; Zhuleva A.Yu.; Anikeeva N.A.

doi:https://doi.org/10.17116/profmed202528041130

OBJECTIVE

To present and summarize information on the diagnostic and prognostic values of the most promising biomarkers for differential diagnosis and assessment of the severity of the course and outcomes of CAP in children.

MATERIALS AND METHODS

A search was conducted for publications on the use of modern markers such as C-reactive protein, procalcitonin, mid-regional proadrenomedullin, presepsin, serum soluble triggering receptor expressed on myeloid cells-1, surfactant protein D, and heparin-binding protein for differential diagnosis and assessment of CAP severity in children. PubMed and MedLine databases were used.

RESULTS

A review of the literature data showed that the above markers, each with its own advantages and limitations, can be considered promising diagnostic and prognostic tools for pediatric CAP. A universal biomarker that can be used to differentially diagnose the etiological factors of CAP and assess the severity of the course and prognosis of the disease has not been identified yet.

CONCLUSION

It is necessary to continue searching for new markers and studying the value of already known ones in assessing the risk of adverse outcomes of community-acquired pneumonia in children.

Keywords:

community-acquired pneumonia

children

biomarkers

differential diagnosis

prognosis

Authors:

Belykh N.A.

Academician I.P. Pavlov Ryazan State Medical University

ORCID: 0000-0002-5533-0205

Zhuleva A.Yu.

Academician I.P. Pavlov Ryazan State Medical University

ORCID: 0000-0002-6926-2418

Anikeeva N.A.

Academician I.P. Pavlov Ryazan State Medical University

ORCID: 0000-0003-1103-2019

Received:

15.11.2024

Accepted:

21.01.2025

Close metadata

References:

Meyer Sauteur PM. Childhood community-acquired pneumonia. European Journal of Pediatrics. 2024;183(3):1129-1136. https://doi.org/10.1007/s00431-023-05366-6
World Health Organization WHO. Pneumonia in children. November 11, 2022. Accessed October 31, 2024. https://www.who.int/ru/news-room/fact-sheets/detail/pneumonia
O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossijskoj Federacii v 2023 godu: Gosudarstvennyj doklad. M.: Federal’naya sluzhba po nadzoru v sfere zashchity prav potrebitelej i blagopoluchiya cheloveka; 2024. Accessed November 04, 2024. (In Russ.). https://www.rospotrebnadzor.ru/documents/details.php?ELEMENT_ID=27779
Pnevmoniya (vnebol`nichnaya). Klinicheskie rekomendacii. 2022—2023—2024 (18.01.2022). Utverzhdeny` Minzdravom Rossii/Soyuz pediatrov Rossii. M.; 2022. (In Russ.).
Yadav KK, Awasthi S. Childhood Pneumonia: What’s Unchanged, and What’s New? Indian Journal of Pediatrics. 2023;90(7):693-699. https://doi.org/10.1007/s12098-023-04628-3
Yun KW, Wallihan R, Juergensen A, et al. Community-Acquired Pneumonia in Children: Myths and Facts. American Journal of Perinatology. 2019; 36(S 02):S54-S57. https://doi.org/10.1055/s-0039-1691801
Ito A, Ishida T. Diagnostic markers for community-acquired pneumonia. Annals of Translational Medicine. 2020;8(9):609. https://doi.org/10.21037/atm.2020.02.182
Barak-Corren Y, Horovits Y, Erlichman M, et al. The prognostic value of C-reactive protein for children with pneumonia. Acta Paediatrica. 2021;110(3):970-976. https://doi.org/10.1111/apa.15580
Tsao YT, Tsai YH, Liao WT, et al. Differential Markers of Bacterial and Viral Infections in Children for Point-of-Care Testing. Trends in Molecular Medicine. 2020;26(12):1118-1132. https://doi.org/10.1016/j.molmed.2020.09.004
Florin TA, Ambroggio L, Brokamp C, et al. Biomarkers and Disease Severity in Children With Community-Acquired Pneumonia. Pediatrics. 2020; 145(6):e20193728. https://doi.org/10.1542/peds.2019-3728
Ross Y, Ballou S. Reliability of C-reactive protein as an inflammatory marker in patients with immune-mediated inflammatory diseases and liver dysfunction. Rheumatology Advances in Practice. 2023;7(2):rkad045. https://doi.org/10.1093/rap/rkad045
Hamade B, Huang DT. Procalcitonin: Where Are We Now?. Critical Care Clinics. 2020;36(1):23-40. https://doi.org/10.1016/j.ccc.2019.08.003
US Food and Drug Administration. FDA clears test to help manage antibiotic treatment for lower respiratory tract infections and sepsis. FDA News Release. 2017. Accessed October 31, 2024. https://www.fda.gov/news-events/press-announcements/fda-clears-test-help-manage-antibiotic-treatment-lower-respiratory-tract-infections-and-sepsis#:~:text=The%20U.S.%20Food%20and%20Drug,stopped%20in%20patients%20with%20sepsis
Zhu S, Zeng C, Zou Y, et al. The Clinical Diagnostic Values of SAA, PCT, CRP, and IL-6 in Children with Bacterial, Viral, or Co-Infections. International Journal of General Medicine. 2021;14:7107-7113. https://doi.org/10.2147/IJGM.S327958
Kakareko K, Rydzewska-Rosołowska A, Rygasiewicz K, et al. Prognostic value of midregional proadrenomedullin in critically ill patients. Polish Archives Of Internal Medicine. 2019;129(10):673-678. https://doi.org/10.20452/pamw.14947
Florin TA, Ambroggio L, Brokamp C, et al. Proadrenomedullin Predicts Severe Disease in Children With Suspected Community-acquired Pneumonia. Clinical Infectious Diseases. 2021;73(3):e524-e530. https://doi.org/10.1093/cid/ciaa1138
Buendgens L, Yagmur E, Ginsberg A, et al. Midregional Proadrenomedullin (MRproADM) Serum Levels in Critically Ill Patients Are Associated with Short-Term and Overall Mortality during a Two-Year Follow-Up. Mediators of Inflammation. 2020;2020:7184803. https://doi.org/10.1155/2020/7184803
Korkmaz MF, Güzel A, Açıkgöz M, et al. Reliability of Pro-adrenomedullin and Interleukin 1β in Predicting Severity of Community-Acquired Pneumonia in Pediatric Patients. Annals of Clinical and Laboratory Science. 2018;48(1):81-89.
Formenti P, Gotti M, Palmieri F, et al. Presepsin in Critical Illness: Current Knowledge and Future Perspectives. Diagnostics (Basel). 2024;14(12):1311. https://doi.org/10.3390/diagnostics14121311
Maddaloni C, De Rose DU, Santisi A, et al. The Emerging Role of Presepsin (P-SEP) in the Diagnosis of Sepsis in the Critically Ill Infant: A Literature Review. International Journal of Molecular Sciences. 2021;22(22):12154. https://doi.org/10.3390/ijms222212154
Galliera E, Massaccesi L, de Vecchi E, et al. Clinical application of presepsin as diagnostic biomarker of infection: overview and updates. Clinical Chemistry and Laboratory Medicine. 2019;58(1):11-17. https://doi.org/10.1515/cclm-2019-0643
Halıcı A, Hür İ, Abatay K, et al. The role of presepsin in the diagnosis of chronic obstructive pulmonary disease acute exacerbation with pneumonia. Biomarkers in Medicine. 2020;14(1):31-41. https://doi.org/10.2217/bmm-2019-0183
Ugajin M, Matsuura Y, Matsuura K, et al. Impact of initial plasma presepsin level for clinical outcome in hospitalized patients with pneumonia. Journal of Thoracic Disease. 2019;11(4):1387-1396. https://doi.org/10.21037/jtd.2019.03.74
Lee KR, Hong DY, Paik JH, et al. Prognostic Value of Plasma Presepsin and Pneumonia Severity Index in Patients with Community-Acquired Pneumonia in the Emergency Department. Medicina. 2022;58(11):1504. https://doi.org/10.3390/medicina58111504
Savić D, Simović A, Marković S, et al. The Role of Presepsin Obtained from Tracheal Aspirates in the Diagnosis of Early Onset Pneumonia in Intubated Newborns. Indian Journal of Pediatrics. 2018;85(11):968-973. https://doi.org/10.1007/s12098-018-2676-2
Yamazaki A, Nukui Y, Kameda T, et al. Variation in presepsin and thrombomodulin levels for predicting COVID-19 mortality. Scientific Reports. 2023;13(1):21493. https://doi.org/10.1038/s41598-023-48633-0
Guarino M, Perna B, Maritati M, et al. Presepsin levels and COVID-19 severity: a systematic review and meta-analysis. Clinical and Experimental Medicine. 2023;23(4):993-1002. https://doi.org/10.1007/s10238-022-00936-8
Lemarié J, Gibot S. Soluble Triggering Receptor Expressed on Myeloid Cells-1: Diagnosis or Prognosis? Critical Care Clinics. 2020;36(1):41-54. https://doi.org/10.1016/j.ccc.2019.08.004
Um YW, Park I, Lee JH, et al. Dynamic Changes in Soluble Triggering Receptor Expressed on Myeloid Cells-1 in Sepsis with Respect to Antibiotic Susceptibility. Infection and Drug Resistance. 2024;17:2141-2147. https://doi.org/10.2147/IDR.S464286
Yang ZQ, Mai JY, Zhu ML, et al. Soluble Triggering Receptors Expressed on Myeloid Cells-1 as a Neonatal Ventilator-Associated Pneumonia Biomarker. International Journal of General Medicine. 2021;14:4529-4534. https://doi.org/10.2147/IJGM.S315987
de Oliveira YLM, de Sá Resende A, Martins-Filho PR, et al. Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies. Inflammopharmacology. 2022;30(3):1037-1045. https://doi.org/10.1007/s10787-022-00972-6
de Souza Xavier Costa N, da Costa Sigrist G, Schalch AS, et al. Lung tissue expression of epithelial injury markers is associated with acute lung injury severity but does not discriminate sepsis from ARDS. Respiratory Research. 2024;25(1):129. https://doi.org/10.1186/s12931-024-02761-x
Dahmer MK, Flori H, Sapru A, et al. Surfactant Protein D Is Associated With Severe Pediatric ARDS, Prolonged Ventilation, and Death in Children With Acute Respiratory Failure. Chest. 2020;158(3):1027-1035. https://doi.org/10.1016/j.chest.2020.03.041
Saleh NY, Ibrahem RAL, Saleh AAH, et al. Surfactant protein D: a predictor for severity of community-acquired pneumonia in children. Pediatric Research. 2022;91(3):665-671. https://doi.org/10.1038/s41390-021-01492-9
Peukert K, Sauer A, Seeliger B, et al. Increased Alveolar Epithelial Damage Markers and Inflammasome-Regulated Cytokines Are Associated with Pulmonary Superinfection in ARDS. Journal of Clinical Medicine. 2023; 12(11):3649. https://doi.org/10.3390/jcm12113649
Liu P, Chen D, Lou J, et al. Heparin-binding protein as a biomarker of severe sepsis in the pediatric intensive care unit: A multicenter, prospective study. Clinica Chimica Acta. 2023;539:26-33. https://doi.org/10.1016/j.cca.2022.11.028
Kahn F, Tverring J, Mellhammar L, et al. Heparin-Binding Protein as a Prognostic Biomarker of Sepsis and Disease Severity at the Emergency Department. Shock. 2019;52(6):e135-e145. https://doi.org/10.1097/SHK.0000000000001332
Saridaki M, Metallidis S, Grigoropoulou S, et al. Integration of heparin-binding protein and interleukin-6 in the early prediction of respiratory failure and mortality in pneumonia by SARS-CoV-2 (COVID-19). European Journal of Clinical Microbiology and Infectious Diseases. 2021;40(7):1405-1412. https://doi.org/10.1007/s10096-020-04145-7
Cai R, Li H, Tao Z. Heparin-binding protein and procalcitonin in the diagnosis of pathogens causing community-acquired pneumonia in adult patients: a retrospective study. Peer J. 2021;9:e11056. https://doi.org/10.7717/peerj.11056
Paulsson M, Thelaus L, Riesbeck K, et al. Heparin-binding protein in lower airway samples as a biomarker for pneumonia. Respiratory Research. 2021;22(1):174. https://doi.org/10.1186/s12931-021-01764-2
Li S, Xu Y, Wu Y, et al. Heparin-Binding Protein: A Prognostic Biomarker Associated with Severe or Complicated Community-Acquired Pneumonia in Children. Journal of Inflammation Research. 2023;16:321-331. https://doi.org/10.2147/JIR.S393600
Huang C, Zhang C, Zhang J, et al. Heparin-Binding Protein in Critically Ill Children with Severe Community-Acquired Pneumonia. Frontiers in Pediatrics. 2021;9:759535. https://doi.org/10.3389/fped.2021.759535
Liu XY, Zhang XF, Li J, et al. Value of heparin-binding protein in the diagnosis of severe adenovirus pneumonia in children. Zhongguo Dang Dai Er Ke Za Zhi. 2022;24(9):1014-1019. https://doi.org/10.7499/j.issn.1008-8830.2203157